Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage trial are ...

Some of the best growth stocks aren't household names, at least not yet. These up-and-coming companies are still relatively early in their growth cycle. Investors could earn enormous returns as they ...

NPR's Up First is the news you need to start your day. The three biggest stories of the day, with reporting and analysis from NPR News — in 10 minutes. Available weekdays at 6:30 a.m. ET, with hosts ...

July 17, 2026 • President Trump gave a primetime speech raising claims of voting vulnerabilities but offered no new evidence. And, at least 2 people have died in major flooding in Texas. July 17, 2026 ...

Mash-up Episode 161213 / 13 Dec 2016 Summary What happens when we take two already made things and combine them to make something new? Dan and Feifei will clue you in! Transcript Dan Hello and welcome ...

Copyright 2026 The Denver Post. All rights reserved. The use of any content on this website for the purpose of training artificial intelligence systems, algorithms ...